Weight loss medications have become a hot topic in recent years, with drugs like Ozempic and Wegovy, containing the active ingredient semaglutide, showing remarkable results in reducing weight. However, despite their effectiveness for some individuals, there are users who do not experience the desired benefits. What causes this variation in response?
How Does Semaglutide Work?
Semaglutide is part of a class of drugs that mimic natural intestinal hormones, working by stimulating GLP-1 receptors. After eating, a similar hormone is released from the intestines, contributing to weight regulation through several mechanisms. This hormone enhances insulin secretion, helping to control blood sugar levels, and slows stomach emptying, providing a longer feeling of fullness. Additionally, it suppresses hunger centers in the brain.
Factors Affecting Non-Response
Despite the benefits these medications offer, not everyone achieves the same results. Research indicates that between 10% and 30% of users do not lose significant weight and are termed “non-responders.” This may be due to incorrect adherence to the medication regimen or premature discontinuation before reaching the optimal dose. Furthermore, metabolic factors like insulin resistance can reduce the drug’s effectiveness.
Gender and Genetics as Influential Factors
Studies have shown that women may benefit more from these drugs compared to men, attributed to differences in hormone levels such as estrogen, which enhances insulin sensitivity and GLP-1 secretion. Research has also revealed genetic mutations in some individuals that may lead to resistance to the drug’s effects, such as changes in the gene responsible for the PAM enzyme.
The Role of Psychological and Behavioral Factors
The causes of obesity vary between psychological and behavioral factors. People who experience emotional hunger do not benefit significantly from these drugs as they do not address the root causes of anxiety or depression that may drive them to eat. Here, psychological therapies, such as cognitive behavioral therapy, can be helpful. For those who suffer from hunger due to daily habits, it might be better to guide them towards other medications or enhance appropriate dietary strategies.
Conclusion
Weight loss drugs like semaglutide offer promising possibilities in the field of obesity treatment, but they are not a universal solution for everyone. We should move towards developing precise obesity medicine that relies on assessing each person’s genetic and individual characteristics to ensure effective treatment. A deeper understanding of genetics and environmental factors is a crucial step towards providing personalized and effective treatments for individuals.